Diabetes Mellitus (Pediatric) Signs And Symptoms

Malaysia
Search
Sign In

Paediatrics Search

Paediatrics

Paediatrics

Home News Diseases Conferences Special Reports Multimedia

DIABETES MELLITUS (PEDIATRIC)

Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
It can occur at any age and the earlier the onset, the more serious is the long-term damage, dysfunction and failure of various organs due to the chronic hyperglycemia with diabetes mellitus patients having <10 year in life span compared to non-DM patients.
Type 1 DM patients have complete insulin deficiency due to beta-cell destruction. It may be immune-mediated or idiopathic. More commonly occurs in children 7-15 year of age, but may occur at any age.
Type 2 DM patients have insulin resistance and relative insulin deficiency.
Neonatal DM is hyperglycemia that occurs in the first 6 months of life.

Signs and Symptoms

Introduction

Can occur at any age & the earlier the onset, the more serious the long-term damage, dysfunction, & failure of various organs due to the chronic hyperglycemia w/ diabetes mellitus (DM) patients having <10 years in life span compared to non-DM patients

Definition

Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both

Signs and Symptoms

Type 1 Diabetes Mellitus (DM)

Hyperglycemia, glycosuria, ketonemia & ketonuria w/ the following for several week:
- Polyuria
- Polydipsia
- Polyphagia
- Weight loss
May also present as severe dehydration, shock & diabetic ketoacidosis (DKA)

Type 2 Diabetes Mellitus (DM)

Overweight or obese
Glycosuria w/o ketonuria
- Some may present w/ ketonuria
Absent or mild polyuria
May present w/ ketoacidosis associated w/ stress, infection or other illness
Acanthosis nigricans
Polycystic ovary syndrome (PCOS)

Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!

Enzalutamide shows potential survival benefit in metastatic hormone-sensitive prostate cancer

Roshini Claire Anthony, 4 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.